20-F: Biophytis S.A. Files 20-F Annual Report, Outlines Financials and Strategic Developments

Biophytis S.A. releases its 20-F filing, detailing financial results, ongoing clinical programs, and future strategies in the biotechnology sector.

Summary

• Biophytis S.A., a clinical-stage biotechnology company, has filed its 20-F annual report.
• The report highlights the company's focus on developing therapeutics for age-related degenerative diseases.
• A key focus is on BIO101 (20-hydroxyecdysone), a drug candidate in clinical development for sarcopenia, COVID-19-related respiratory issues, and Duchenne Muscular Dystrophy (DMD).
• BIO201, another drug candidate, is in preclinical development for retinopathies like dry AMD.
• The company is also working on life-cycle extension drug candidates, BIO103 and BIO203.
• Biophytis reported losses of 31.2 million, 24.3 million, and 17.6 million for the years 2021, 2022, and 2023, respectively.
• As of December 31, 2023, the company had cash and cash equivalents of 5.6 million.
• The company anticipates needing additional funding to continue its clinical trials and research and development activities.
• There is a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern.
• The company plans to seek additional funding through collaborations, equity offerings, debt financings, or public funding.
• Biophytis is implementing a remediation plan to address a material weakness in internal control over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical programs, the company's financial situation raises concerns about its ability to continue as a going concern. The material weakness in internal control over financial reporting also adds to the negative sentiment.

Positives

• BIO101 (20-hydroxyecdysone) showed a statistically significant reduction in the risk of respiratory failure or early death in COVID-19 patients.
• The company has received authorization to conduct a Phase 3 clinical trial for BIO101 (20-hydroxyecdysone) in sarcopenia.
• The company is exploring BIO201 as a potential treatment for Stargardt disease.
• The company is implementing a remediation plan to address a material weakness in internal control over financial reporting.

Negatives

• The company has incurred significant losses since its inception and anticipates continuing to incur losses.
• The company's existing capital resources are not sufficient to cover its operating needs for at least the next 12 months.
• There is a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified.

Risks

• The company may not be able to obtain regulatory approval or emergency use authorization for its drug candidates.
• The company may have difficulty enrolling patients or finding and retaining investigators for clinical studies.
• The company's drug candidates could cause undesirable side effects.
• The company may face significant competition.
• The company may be unable to comply with environmental laws and regulations.
• The company may be unable to maintain effective internal control over financial reporting.

Future Outlook

The company plans to continue its clinical trials and research and development activities, seeking additional funding through collaborations, equity offerings, debt financings, or public funding. The company expects to incur additional costs associated with operating as a public company in the United States.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. The company faces competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions.

Comparison to Industry Standards

• The report mentions competitors in the fields of sarcopenia, COVID-19, DMD, and dry AMD.
• For COVID-19, the company competes with companies that have developed anti-viral agents, monoclonal antibodies, and anti-inflammatory/immune-suppressing drugs.
• For DMD, the company competes with companies that have developed targeted therapies and gene therapies.
• For dry AMD, the company competes with companies that are developing drugs to treat this disease using different technologies (e.g., cellular and gene therapy, integrin regulation, and others), for example, Allegro Ophthalmics, Apellis Pharmaceuticals, Kodiak Sciences, Astellas, Hemera Biosciences, Iveric Bioscience and Roche and Stealth Biotherapeutics.

Legal Proceedings

• The company is involved in a legal proceeding with Negma Group Limited.

Related Party Transactions

• The company has entered into an intellectual property agreement with its CEO, Stanislas Veillet.
• The company has entered into a current account advance agreement with Biophytis, Inc.
• The company is party to a debt compensation agreement with Biophytis, Inc.
• The company has entered into a services agreement with Biophytis, Inc.
• The company has entered into a services agreement with Successful Life SAS, in which Jean Mariani has a controlling interest.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Shareholders may experience dilution as a result of future equity offerings.
• Shareholders may be impacted by the company's ability to secure additional financing.
• Employees may be impacted by potential reductions in spending or curtailment of planned programs.
• Patients may be impacted by the company's ability to continue developing and commercializing its drug candidates.

Next Steps

• The company plans to continue its clinical trials and research and development activities.
• The company plans to seek additional funding through collaborations, equity offerings, debt financings, or public funding.
• The company plans to implement a remediation plan to address a material weakness in internal control over financial reporting.

Key Dates

Keywords

BIO101, BIO201, sarcopenia, COVID-19, DMD, retinopathies, clinical trials, financial results, Biophytis, biotechnology